Interesting that Array is basically unchanged today with InterMune up mid-upper twenties. OK the nasdaq is down big and the company has had a nice rise year to date and I didn't like the shelf they filed...
I don't know enough about it but they seem to be a nice little company with a lot of potential royalties and starting to develop their own compounds too.
> ITMN ARRY – In fairness to my guess the [royalty] rate goes up if they decide not to copromote in the US…<
True. Moreover, ITMN’s relatively low royalty rate outside the U.S. is a tradeoff for Roche’s concession to pay a higher rate of the global program costs (67%) than Roche’s share of U.S. profits (50%). All told, a very good deal for ITMN, IMO.
>…I am fairly certain Array will also get low-mid single digits of Milestone payments too.<
That will hardly make a dent in the hundreds of millions of milestones ITMN could receive.
ITMN refers to ARRY as their “partner” rather than their “licensor.” How is it that ARRY is getting so little out of all this? T.i.a.
News 
Market Data 
Discover 
AI
